THE PATHOLOGY OF SUDDEN UNEXPECTED DEATH IN CHILDHOOD = LA PATHOLOGIE DES MORTS SUBITES, IMPREVUES, CHEZ L'ENFANTAHERNE W.1972; FORENS. SCI. SOC., J.; G.B.; DA. 1972; VOL. 12; NO 4; PP. 585-586 (4P.); BIBL. 1REF.Serial Issue

THE SIGNIFICANCE OF LYMPHOCYTIC INFILTRATION IN NEUROBLASTOMA = LA SIGNIFICATION DE L'INFILTRATION LYMPHOCYTAIRE DANS LE NEUROBLASTOMELAUDER I; AHERNE W.1972; BRIT. J. CANCER; G.B.; DA. 1972; VOL. 26; NO 4; PP. 321-330; BIBL. 1P.Serial Issue

FAMILIAL NEUROBLASTOMA: REPORT OF TWO SIB PAIRS = NEUROBLASTOME FAMILIAL: OBSERVATION DE DEUX COUPLES DE FRERE ET SOEURWAGGET J; AHERNE G; AHERNE W et al.1973; ARCH. DIS. CHILDH.; G.B.; DA. 1973; VOL. 48; NO 1; PP. 63-66; BIBL. 4REF.Serial Issue

DEGREE OF TOLERANCE AND THE RELATIONSHIP BETWEEN PLASMA MORPHINE CONCENTRATION AND PUPIL DIAMETER FOLLOWING INTRAVENOUS HEROIN IN MAN.TRESS KH; EL SOBKY AA; AHERNE W et al.1978; BRIT. J. CLIN. PHARMACOL.; G.B.; DA. 1978; VOL. 5; NO 4; PP. 299-303; BIBL. 3 REF.Article

THE CHARACTERISTICS OF FERRITIN FROM HUMAN TISSUES, SERUM AND BLOOD CELLS = CARACTERISTIQUES DE LA FERRITINE DES TISSUS HUMAINS, DU SERUM ET DES CELLULES DU SANGWORWOOD M; AHERNE W; DAWKINS S et al.1975; CLIN. SCI. MOLEC. MED.; G.B.; DA. 1975; VOL. 48; NO 5; PP. 441-451; BIBL. 25REF.Article

Interference by antifolate drugs in a folate competitive protein-binding assayHARDCASTLE, A; CLARKE, S; AHERNE, W et al.Cancer chemotherapy and pharmacology. 1997, Vol 39, Num 6, pp 552-553, issn 0344-5704Article

Serum kinetics of the anti-cancer agent 4-hydroxyandrostenedione in the ratKHUBIEH, J; AHERNE, W; CHAKRABORTY, J et al.Cancer chemotherapy and pharmacology. 1990, Vol 26, Num 5, pp 330-332, issn 0344-5704, 3 p.Article

Development of an enzyme-linked immunosorbent assay for isoproturon in waterKATMEH, M. F; FROST, G; AHERNE, W et al.Analyst (London. 1877. Print). 1994, Vol 119, Num 3, pp 431-435, issn 0003-2654Article

Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral wartsJAMES, M. P; COLLIER, P. M; AHERNE, W et al.Journal of the American Academy of Dermatology. 1993, Vol 28, Num 6, pp 933-937, issn 0190-9622Article

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancerPOPAT, S; CHEN, Z; ZHAO, D et al.Annals of oncology. 2006, Vol 17, Num 12, pp 1810-1817, issn 0923-7534, 8 p.Article

Metabolism, excretion and pharmacokinetics of a single dose of [¹⁴C]-raltitrexed in cancer patientsBEALE, P; JUDSON, I; HANWELL, J et al.Cancer chemotherapy and pharmacology. 1998, Vol 42, Num 1, pp 71-76, issn 0344-5704Article

A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of ¹⁴C-labelled drugJUDSON, I. R; BEALE, P. J; TRIGO, J. M et al.Investigational new drugs. 1999, Vol 17, Num 1, pp 49-56, issn 0167-6997Article

A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DRAYTER, S; ELLIOTT, R; LORD, C. J et al.Oncogene (Basingstoke). 2008, Vol 27, Num 8, pp 1036-1044, issn 0950-9232, 9 p.Article

Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatinLINKS, M; WATSON, S; LETHLEAN, K et al.Cancer investigation. 1999, Vol 17, Num 7, pp 479-485, issn 0735-7907Article

A phase i pharmacokinetic and pharmacodynamic study of BGC933 i and carboplatin in relapsed gynaecological malignanciesBENEPAL, T; JACKMAN, A; GORE, M et al.British journal of cancer. 2005, Vol 93, Num 8, pp 868-875, issn 0007-0920, 8 p.Article